|Bid||7.95 x 900|
|Ask||9.00 x 900|
|Day's Range||7.66 - 8.04|
|52 Week Range||4.10 - 14.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.20|
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reiterated its ongoing efforts to fundamentally transform the company. President and Chief Executive Officer Saeed Motahari joined INSYS in April 2017. Nearly 50 percent of the company’s field force are new to the company.
LAS VEGAS, NV / ACCESSWIRE / June 18, 2018 / President Donald Trump said recently that he was inclined to support a bipartisan effort in Congress to ease the U.S. ban on marijuana, a proposal that would ...
NEW YORK, NY / ACCESSWIRE / June 15, 2018 / U.S. market ended mostly higher on Thursday, as rallies from tech sector drove the Nasdaq to new intraday and closing records. The Dow Jones Industrial Average ...
Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely dose of epinephrine to avoid a potentially fatal outcome. INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. In a pharmacokinetics study involving 60 people with seasonal allergies, preliminary results showed that the bioavailability of the company’s novel, proprietary formulation of epinephrine delivered intranasally was similar to that of intramuscular injection with EpiPen® (0.3 mg).
Today, I will be analyzing INSYS Therapeutics Inc’s (NASDAQ:INSY) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affectRead More...
A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine. Dr. Michael Frey, 46, pleaded guilty on Monday in federal court in Fort Myers, Florida, to conspiring to receive kickbacks from a medical equipment provider and a pharmacy sales representative.
PHOENIX, June 04, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...
Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc, accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug. The lawsuit by Minnesota Attorney General Lori Swanson alleged that the company marketed the opioid drug intended to alleviate pain in cancer patients for unapproved uses. It added to the legal woes of Insys, whose former top executives have been caught up in a federal criminal investigation involving the drug, Subsys.
ST. PAUL, Minn. (AP) — Minnesota's attorney general is suing an Arizona-based pharmaceutical company, alleging it illegally marketed a painkiller made from the synthetic opioid fentanyl.
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted not to recommend approval of the company’s New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. “We appreciate the panelists’ perspective and guidance,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life.
Its ex-chief executive officer, John Kapoor, and several former top executives have been charged with conspiracy to illegally distribute Subsys, a mouth-spray form of fentanyl that is approved by the Food and Drug Administration to treat cancer-related pain. Mr. Kapoor has denied wrongdoing and pleaded not guilty. Shares of Insys fell 6% on Tuesday.
Insys Therapeutics Inc said on Tuesday that it believed a previously estimated $150 million would be sufficient to cover expenses from an ongoing litigation related to the company's sales practises. The news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors. The company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday.
In December 2013, INSYS received a subpoena from the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS), which notified the company of the commencement of an investigation by the DOJ’s Civil Division into the company’s sales and commercial practices and resulted in the company’s corresponding public disclosure. As is often the case, this four-and-a-half-year investigation has been conducted in concert with certain whistleblower litigation that was filed under seal prior to and during the course of the DOJ’s investigation.
The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl. Six U.S. states - California, Colorado, Indiana, New York, North Carolina and Virginia - also joined whistleblower litigation against Insys, according to the filing in U.S. District Court in Los Angeles.
The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit. According to a filing made public on Monday in Los Angeles federal court, the department and six U.S. states intervened in whistleblower litigation against Insys, which has said it had been trying to negotiate a settlement of a federal probe into its marketing of fentanyl-based Subsys. The litigation followed a wave of related criminal cases against medical practitioners and former executives and sales representatives employed by Chandler, Arizona-based Insys, including its billionaire founder John Kapoor.
Shares of the small-cap biotech climbed following news that the company would proceed with inhalation-based dronabinol delivery tests.
The Chandler, Arizona-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 19 cents per share. The results matched Wall Street ...
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has agreed to an exclusive license partnership with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in the Middle East. Based in Dubai with satellite offices across the Gulf Cooperation Council, Lunatus will be the exclusive licensee for SUBSYS® in Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates. “Partnering with Lunatus will make SUBSYS® available to adult cancer patients in the licensed territory who are suffering episodes of breakthrough cancer pain despite receiving around-the-clock opioid therapy,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.
Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS ® revenue continue. PHOENIX, May 08, 2018-- INSYS Therapeutics, Inc., a leader in the development, ...
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss Canopy Growth Corp (CGC), which begins trading on NYSE today and is the first pure cannabis play to achieve a listing on the exchange.